Macugen Approval Awaits CMC Review; Committee Supports Efficacy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The final decision on Pfizer/Eyetech’s Macugen awaits review of the chemistry and manufacturing sections of the NDA, FDA said during the Dermatologic & Ophthalmic Drug Products Advisory Committee’s Aug. 27 review of the clinical data.